Form 4: BMY Executive Meyers Reports RSU Vesting & Tax Withholding

Bristol-Myers Squibb EVP Gregory Scott Meyers reported the vesting of 2,543 restricted stock units and the withholding of 833 shares for tax purposes.

Summary

• Gregory Scott Meyers, EVP, Chief Digital & Technology Officer at Bristol-Myers Squibb Company (BMY), reported transactions on February 1, 2026.
• 2,543 shares of common stock were acquired upon the vesting of restricted stock units at a price of $0.
• 833 shares of common stock were disposed of at a price of $55.05 to cover tax obligations related to the RSU vesting.
• Following these transactions, Meyers beneficially owns 21,428 shares of Bristol-Myers Squibb common stock.
• The restricted stock units vest annually in four equal installments, with the first installment having occurred on February 1, 2023.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, reflecting routine executive compensation activities without any significant positive or negative implications for the company's operational or financial performance.

Positives

• The executive's beneficial ownership of common stock remains substantial at 21,428 shares, indicating continued alignment with shareholder interests.
• The vesting of restricted stock units represents a planned compensation event, reflecting the executive's ongoing tenure and performance.

Negatives

• 833 shares were disposed of to cover tax liabilities, which is a routine event for RSU vesting but reduces the executive's direct shareholding.

Future Outlook

The restricted stock units are structured to vest annually in four equal installments, indicating a pre-determined long-term incentive plan for the executive.

Industry Context

StockSavvy.ai notes that the vesting of restricted stock units and subsequent tax withholding is a standard practice in executive compensation across the pharmaceutical industry, aligning executive incentives with long-term company performance. This routine transaction does not indicate any specific strategic shift or operational change for Bristol-Myers Squibb.

Stakeholder Impact

• Minimal direct impact on shareholders as this is a routine executive compensation event.
• Positive for the executive as it represents a realization of long-term incentives.

Next Steps

• Future annual vesting installments of restricted stock units are expected as per the original grant terms, with the first installment having occurred on February 1, 2023.

Key Dates

Keywords

Bristol-Myers Squibb, BMY, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Executive Compensation, Gregory Scott Meyers, Share Ownership